252723-16-3 Usage
General Description
7-Benzenesulfonyl-4-chloro-6-methyl-7H-pyrrolo[2,3-d]pyrimidine is a chemical compound with the molecular formula C16H12ClN3O2S. It is a pyrrolopyrimidine derivative with a sulfonamide group attached to the benzene ring. 7-Benzenesulfonyl-4-chloro-6-methyl-7H-pyrrolo[2,3-d]pyri midine is used as a building block in the synthesis of various biologically active compounds, particularly in the pharmaceutical industry. It exhibits potential pharmacological activities and has been studied for its antitumor and antiviral properties. Additionally, its structure and reactivity make it an interesting target for medicinal chemistry research in the development of new drugs.
Check Digit Verification of cas no
The CAS Registry Mumber 252723-16-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,5,2,7,2 and 3 respectively; the second part has 2 digits, 1 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 252723-16:
(8*2)+(7*5)+(6*2)+(5*7)+(4*2)+(3*3)+(2*1)+(1*6)=123
123 % 10 = 3
So 252723-16-3 is a valid CAS Registry Number.
252723-16-3Relevant articles and documents
ATROPISOMERISM FOR ENHANCED KINASE INHIBITOR SELECTIVITY
-
, (2019/01/10)
The invention provides a series of conformationally stable and selective kinase inhibitors, and methods of using the kinase inhibitors. The effect of atropisomerism on kinase selectivity was assessed, finding improved selectivity compared to rapidly inter
TREATMENT OF DRY EYE
-
, (2014/02/16)
The present disclosure provides a method of treating dry eye by inhibition of Bruton's tyrosine kinase (hereinafter "BTK") inhibitors, pharmaceutical formulations comprising the same, and processes for preparing such compounds.
PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS
-
Page/Page column 53; 54, (2014/12/12)
The present invention relates to 6-amino-7-deaza-purine derivatives which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity, in particular RET family kinases. The present
